These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21364592)

  • 21. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
    Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
    Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].
    Hori T; Ikehara T; Takatsuka S; Fukuoka T; Tendo M; Tezuka K; Dan N; Nishino H; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):293-5. PubMed ID: 21368498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
    Kitagawa M; Shimura T; Yamada T; Ebi M; Hirata Y; Mizoshita T; Tanida S; Kataoka H; Kamiya T; Joh T
    Anticancer Res; 2012 May; 32(5):1763-8. PubMed ID: 22593458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].
    Hu FK; Shen J; Gao SW
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1915-1918. PubMed ID: 29996281
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
    Hamakawa T; Kurokawa Y; Takiguchi S; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Dok Y
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2342-4. PubMed ID: 22202376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
    Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
    Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
    Nakata B; Tsuji A; Mitachi Y; Taenaka N; Kamano T; Oikawa K; Onoda N; Kambe M; Takahashi M; Shirasaka T; Morita S; Sakamoto J; Tanaka Y; Saji S; Hirakawa K
    Oncology; 2010; 79(5-6):337-42. PubMed ID: 21430401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
    Uchima Y; Kosaka K; Kimura K; Okita Y; Sim JK; Aomatsu N; Hirata K; Lee WH; Lee T; Nishii T; Tei S; Takeuchi K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
    Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
    Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
    Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
    Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
    Han JY; Yoon KA; Park JH; Lee YJ; Lee GK; Han JH; Yoon SJ; Yun T; Kim HT; Lee JS
    Cancer; 2011 Jul; 117(14):3201-8. PubMed ID: 21264830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.